Fulcrum Therapeutics Inc.

NASDAQ: FULC · Real-Time Price · USD
6.81
0.21 (3.18%)
At close: Aug 15, 2025, 3:59 PM
6.82
0.15%
After-hours: Aug 15, 2025, 04:10 PM EDT

Fulcrum Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Revenue
n/a n/a n/a n/a 80M n/a 871K 759K 880K 295K 685K 1.18M 1.88M 2.59M 5.06M 4.93M 4.38M
Cost of Revenue
n/a n/a n/a n/a 17.26M 479K 508K 500K 600K 566K 591K 600K 25.02M 536K 621K 17.08M 17.38M
Gross Profit
n/a n/a n/a n/a 62.74M -479K 363K 259K 280K -271K 94K 583K -23.14M 2.06M 4.44M -12.14M -13M
Operating Income
-19.82M -20.4M -19.43M -25.13M 52.49M -29.83M -27.99M -27.44M -27.29M -27.94M -27.97M -24.36M -34.23M -26M -23.56M -20.77M -19.68M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a 3.51M n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-17.3M -17.66M -16.57M -21.7M 55.41M -26.87M -24.76M -24.02M -23.78M -24.78M -26.14M -23.74M -34.07M -25.93M -23.48M -20.72M -19.65M
Net Income
-17.3M -17.66M -16.57M -21.7M 55.41M -26.87M -24.76M -24.02M -23.78M -21.62M -23.63M -24.05M -34.07M -25.86M -23.48M -20.72M -19.65M
Selling & General & Admin
6.83M 7M 7.72M 8.42M 10.25M 10.06M 9.36M 9.96M 10.32M 11.52M 10.13M 9.71M 11.1M 10.76M 9.71M 8.63M 6.68M
Research & Development
12.99M 13.4M 11.34M 14.64M 17.26M 19.29M 19M 18.24M 17.85M 16.71M 18.57M 15.37M 25.02M 17.83M 18.91M 17.08M 17.38M
Other Expenses
n/a n/a n/a 2.06M n/a n/a n/a 3.42M 3.51M 3.16M 1.84M 617K 165K 70K 75K 54K 34K
Operating Expenses
19.82M 20.4M 19.43M 25.13M 27.51M 29.36M 28.36M 28.2M 28.17M 28.23M 28.7M 25.07M 36.12M 28.59M 28.62M 25.7M 24.06M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a -508K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
n/a 20.4M 19.43M 25.13M 27.51M 29.83M 28.86M 28.2M 28.17M 28.23M 28.7M 25.07M 36.12M 28.59M 28.62M 25.7M 24.06M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a -3.16M -2.5M 313K -24K -70K n/a 19K -28K
Shares Outstanding (Basic)
62.54M 62.48M 53.95M 62.41M 62.2M 61.98M 61.87M 61.82M 61.79M 59.72M 52.08M 46.21M 40.89M 40.64M 40.58M 36.61M 32.64M
Shares Outstanding (Diluted)
62.54M 62.48M 53.95M 62.41M 63.59M 61.98M 61.87M 61.82M 61.79M 59.72M 52.08M 46.21M 40.89M 40.64M 40.58M 36.61M 32.64M
EPS (Basic)
-0.28 -0.28 -0.31 -0.35 0.89 -0.43 -0.4 -0.39 -0.38 -0.36 -0.45 -0.52 -0.83 -0.64 -0.58 -0.57 -0.6
EPS (Diluted)
-0.28 -0.28 -0.31 -0.35 0.87 -0.43 -0.4 -0.39 -0.38 -0.36 -0.45 -0.52 -0.83 -0.64 -0.58 -0.57 -0.6
EBITDA
-19.82M -20.05M -19.06M -22.69M 55.81M -29.36M -27.48M -26.91M -26.73M -27.37M -27.42M -23.28M -33.56M -25.46M -22.94M -20.15M -19.01M
EBIT
-17.3M -20.4M -19.43M -23.06M 55.41M -29.83M -27.99M -27.44M -27.29M -27.94M -28.01M -23.89M -34.23M -26M -23.56M -20.77M -19.68M
Depreciation & Amortization
n/a 353K 369K 369K n/a 479K 508K 500K 600K 566K 591K 600K 700K 536K 621K 600K 700K